As humanity contemplates the expansion into space, a compelling reason may emerge from the realm of biotechnology. A recent study led by Srivatsan Raman at the University of Wisconsin-Madison, published in PLOS Biology, investigates the potential of genetically modified bacteriophages to target antibiotic-resistant bacteria, presenting a novel business case for space exploration.
Experimental Design and Conditions
The experiment, launched in September 2020, utilized specialized cryovials developed by Rhodium Scientific to maintain a storage temperature of -80℃ during transport to the International Space Station (ISS). Prior to the launch, researchers curated a library of 1,660 pre-modified phage variants, aiming to observe which variants would prevail in the unique environmental conditions of space.
To establish a control, the same phage and bacterial combinations were maintained on Earth, allowing for a comparative analysis of their evolutionary processes in microgravity versus terrestrial conditions. Initial observations revealed a significant difference: space-based bacteriophages took considerably longer to eliminate their bacterial counterparts, with Earth-bound phages achieving this in approximately 2-4 hours.
Impact of Microgravity on Bacteria and Phages
The slower action of space phages was attributed to the absence of convection in microgravity, which hindered the movement of solutions. Consequently, the E. coli bacteria experienced stress due to waste accumulation and limited nutrient availability. In response, the bacteria underwent mutations, specifically altering the gene mlaA, which is crucial for phospholipid transport within their membranes. This mutation caused phospholipids to migrate to the surface, impacting how phages interacted with the bacteria.
On Earth, phages adapted through conventional evolutionary changes, while space phages developed hydrophobic substitutions in their Receptor Binding Protein, enhancing their ability to attach to the altered bacterial membranes.
Implications for Antibiotic Resistance
Upon returning to Earth, the mutated phages demonstrated an enhanced capacity to target bacteria responsible for urinary tract infections (UTIs), which are notoriously resistant to antibiotics. Interestingly, the Earth-bound phage variants struggled against the same antibiotic-resistant UTI bacteria. The researchers suggest that the stressors faced by bacteria in the human urinary tract may mimic the conditions experienced by their space counterparts, leading to similar evolutionary adaptations.
This research hints at a promising avenue for developing bioreactors in space to produce potent phages capable of combating antibiotic resistance on Earth, potentially paving the way for a multi-billion dollar industry. However, significant challenges remain, including the need for larger facilities than the ISS to scale such operations.
While the journey towards practical applications is still in its infancy, the study underscores the fascinating ways in which evolutionary dynamics can shift in different environments, with the hope that these insights may one day yield substantial benefits for humanity.
This article was produced by NeonPulse.today using human and AI-assisted editorial processes, based on publicly available information. Content may be edited for clarity and style.
